Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.
Neurocrine was cleared by the FDA to market its Parkinson's treatment Ongentys, which it says helps curb muscle stiffness, tremors and slow movement.
NBIX earnings call for the period ending March 31, 2020.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Idorsia Ltd (SIX: IDIA) today announced, following Investigational New Drug (IND) application acceptance by the U.S. Food and Drug Administration (FDA), Neurocrine Biosciences has exercised its option to license the global rights of Idorsia's ACT-709478. Neurocrine Biosciences plans to initiate a Phase II study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Idorsia Ltd (SIX: IDIA) today announced, following Investigational New Drug (IND) application acceptance by the U.S. Food and Drug Administration (FDA), Neurocrine Biosciences has exercised its option to license…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, May 12, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
Neurocrine Biosciences is the IBD Stock Of The Day as shares consolidate following the biotech company's strong first-quarter report. Ingrezza sales held up better than expected.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, May 12, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2020 and provided revised full-year 2020 financial expense guidance.
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NBIX earnings call for the period ending March 31, 2020.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Arcturus Therapeuti…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the RBC Capital Markets 2020 Global Healthcare Conference at 3:40 p.m. ET on Tuesday, May 19, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
SAN DIEGO, May 5, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, May 12, 2020. Kevin Gorman, Chief Executive Officer, will present at t…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Platform b…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, June 2, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, June 2, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
It has been noted ad nauseam that the stock market doesn't appear to reflect the worst economic slowdown since the Great Depression. The Dow Jones Industrial Average is down "only" 17% for the year to date, while the S&P; 500 is off "just" 11%.If that bothers…
Shares of Neurocrine Biosciences Inc. gained 2.8% in trading on Monday after the company said the Food and Drug Administration had approved its Parkinson's disease drug Ongentys. The daily oral treatment can be used as an add-on treatment to levodopa and carb…
Neurocrine (NBIX) delivered earnings and revenue surprises of 46.43% and 8.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
One thing nearly everyone can agree on about the past decade is that it has been very, very good for stock market investors. The Russell 1000 large-company index, which tracks the 1,000 biggest U.S. stocks by market value, has gained roughly 252% since the start of the 2010s, including reinvested dividends.Some stocks have done far better. Microsoft (MSFT) awoke from its long slumber and jumped 545% over the past decade. Dollar General (DG) made a lot of bucks, gaining 632%. And Ulta Beauty (ULTA) has made a lovely 1,325% gain.But those aren't the tippy-top stocks of the Russell 1000. Not even close.Here are the top 10 large-company stocks of the decade, as well as a look at what put them on top of the heap. We chose the Russell 1000 because it offers an even broader look at the stock market than the S&P; 500, but still excludes smaller companies where extremely outsize gains are more common and can more easily come from a single, quick driver. SEE ALSO: The 20 Best Stocks to Buy for 2020
Q1 2020 Neurocrine Biosciences Inc Earnings Call
How far off is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) from its intrinsic value? Using the most recent financial...
Neurocrine Biosciences, cleared a consolidation. NBIX recently reported strong earnings. Biotech makes a drug to treat side effect of some anti-psychotic medications.
SAN DIEGO, May 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2020 and provided revised full-year 2020 financial expense guidance. "First and foremost, I would li…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Platform beginning May 18, 2020. Online recorded data presentations and several posters of INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD) and ONGENTYS® (opicapone) capsules as an add-on treatment for patients with Parkinson's disease, were selected for the online 2020 AAN Science Highlights Platform which replaced the AAN 72nd annual meeting previously scheduled for April 25–May 1. The abstracts were also published in the online supplement to Neurology.
Neurocrine Biosciences (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Neurocrine (NBIX) delivered earnings and revenue surprises of 46.43% and 8.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences, featured in IBD 50 Stocks To Watch, is approaching a buy point as it tackles neurological diseases and disorders.
Neurocrine Biosciences (NASDAQ: NBIX) had a big day Tuesday, the latest in a string of good days. Net income hit $37.4 million, and the company's cash grew to more than $1 billion. Neurocrine also doubled its number of patients over the same quarter a year ago.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the RBC Capital Markets 2020 Global Healthcare Conference at 3:40 p.m. ET on Tuesday, May 19, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new data from RE-KINECT, the largest ever real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD) demonstrating that the involuntary movements associated with TD can reduce health-related quality of life in patients living with psychiatric disorders.1 Based on clinical assessments, 28% of the 739 patients in this study had clinician-confirmed possible TD and 75% of patients in this group affirmed that they have felt self-conscious or embarrassed about involuntary movements that they could not seem to control.1 In addition, more than 40% of patients with possible TD reported that involuntary movements had "some" or "a lot" of impact on their ability to continue usual activities, such as talking, socializing and being productive.1 These data were recently published in the Journal of Clinical Psychopharmacology and demonstrate the importance of raising awareness of tardive dyskinesia and its impact on patients, especially during Mental Health Month and Tardive Dyskinesia Awareness Week (May 3–9).
Ingrezza sales exceeded Street expectations, and management's pre-Covid-19 efforts in telemedicine may help reduce the outbreak's impact on prescription growth and patient compliance. Management has paused ongoing studies, but is doing the prep work t…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2020 and provided revised full-year 2020 financial expense guidance.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new data from RE-KINECT, the largest ever real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD) demonstrating that the involuntary moveme…
Neurocrine Biosciences has a soon to be blockbuster in Ingrezza that is bringing in solid free cash flow.Neurocrine has used that cash flow to fill its pipeline with several early, mid, and late stage therapies.Neurocrine shares look fairly valued based on bo…